HTG Introduces Oncology Applications and Expands Analytics Capabilities with Release of New Software Update
The HTG EdgeSeq Reveal, launched in January 2019, is a web-based biostatistical analysis software suite designed to accelerate customer research by streamlining their statistical analysis of samples processed with HTG’s RUO profiling assays. Today’s release adds several applications and additional functionalities, including:
- RUO oncology applications – Customers globally are now able to leverage RUO oncology applications specifically built upon, and using data from, the
HTG EdgeSeq Precision Immuno-Oncology Panel(PIP) to generate immune, stroma and tumor microenvironment (TME) scores to better understand factors such as tumor inflammation (Hot versus Cold) and stromal response to a tumor.
HTG EdgeSeq Pan B-Cell Lymphoma Panel– Integration of the recently-launched HTG EdgeSeq Pan B-Cell Lymphoma Panel enables customers globally to assess DLBCL Cell of Origin, in addition to using the analytic capabilities of HTG EdgeSeq Reveal to potentially develop molecular subtyping algorithms to classify and research various aggressive lymphomas.
- RUO menu expansion for Thermo Fisher Scientific Next-Generation Sequencing (NGS) platform – Expanded profiling assay menu allows customers globally to utilize the analytic capabilities of HTG EdgeSeq Reveal with HTG’s entire RUO profiling assay menu, including assays for use with both Illumina, Inc. and Thermo Fisher Scientific NGS platforms.
“This latest release of our HTG EdgeSeq Reveal enhances the functionality available to customers who purchase our RUO profiling assays,” said
HTG is focused on NGS-based molecular profiling. The company’s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. HTG’s customers use its technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries, and ultimately to identify treatment options. Its mission is to empower precision medicine.
Safe Harbor Statement:
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the capabilities and benefits of HTG EdgeSeq Reveal version 3.0, including its RUO oncology applications and potential benefits associated with the
Phone: (617) 430-7577
Source: HTG Molecular Diagnostics, Inc.